RXRX Stock Analysis: Recursion Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.017m USD | 12M Return: -22.1% | Charts, Fundamentals & Technical Analysis

Oncology, Rare Diseases, AI Drug Discovery, Hematology
Total Rating 16
Safety 37
Buy Signal -0.43
Biotechnology
Industry Rotation: +30.9
Market Cap: 2.02B
Avg Turnover: 70.5M
Risk 3d forecast
Volatility76.9%
VaR 5th Pctl12.3%
VaR vs Median-2.94%
Reward TTM
Sharpe Ratio-0.07
Rel. Str. IBD17.1
Rel. Str. Peer Group6.8
Character TTM
Beta2.896
Beta Downside3.375
Hurst Exponent0.531
Drawdowns 3y
Max DD82.09%
CAGR/Max DD-0.21
CAGR/Mean DD-0.30
EPS (Earnings per Share) EPS (Earnings per Share) of RXRX over the last years for every Quarter: "2021-06": -0.31, "2021-09": -0.28, "2021-12": -0.38, "2022-03": -0.33, "2022-06": -0.38, "2022-09": -0.35, "2022-12": -0.3, "2023-03": -0.34, "2023-06": -0.38, "2023-09": -0.43, "2023-12": -0.42, "2024-03": -0.39, "2024-06": -0.4, "2024-09": -0.34, "2024-12": -0.53, "2025-03": -0.5, "2025-06": -0.41, "2025-09": -0.36, "2025-12": -0.21, "2026-03": -0.22,
Last SUE: 0.64
Qual. Beats: 0
Revenue Revenue of RXRX over the last years for every Quarter: 2021-06: 2.5, 2021-09: 2.5, 2021-12: 2.5, 2022-03: 5.299, 2022-06: 7.653, 2022-09: 13.053, 2022-12: 13.676, 2023-03: 12.134, 2023-06: 11.016, 2023-09: 10.102, 2023-12: 10.624, 2024-03: 13.491, 2024-06: 14.404, 2024-09: 26.082, 2024-12: 4.511, 2025-03: 14.745, 2025-06: 19.103, 2025-09: 5.175, 2025-12: 35.538, 2026-03: 6.472,
Rev. CAGR: 14.26%
Rev. Trend: 64.4%
Last SUE: -1.13
Qual. Beats: -1

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Choppy
Below Sma 200d

Tailwinds

Seasonal Tailwind
Confidence

Seasonality 5.2 years of data

Jan +6.7% 25
Feb +3.5% 0
Mar -18.2% 57
Apr +2.0% 9
May +12.1% 30
Jun -2.6% 10
Jul +17.7% 55
Aug -13.0% 22
Sep -0.3% 0
Oct +0.2% 18
Nov +4.4% 0
Dec -7.3% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RXRX Recursion Pharmaceuticals

Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an integrated platform combining biology, chemistry, automation, data science, and engineering to accelerate drug discovery. The company operates in the United States and the United Kingdom and is headquartered in Salt Lake City, Utah, having been incorporated in 2013.

Its pipeline includes REC-4881 in Phase 1b/2 for familial adenomatous polyposis, REC-617, REC-1245, and REC-3565 in Phase 1/2 for various cancers, and REC-4539, an LSD1 inhibitor targeting solid tumors and hematologic malignancies. Preclinical candidates include REC-7735 for HR+ breast cancer and REC-102 for hypophosphatasia. The company has collaboration agreements with Roche & Genentech, Sanofi, Bayer, Tempus, and Takeda Pharmaceutical.

As a clinical-stage biotech, Recursion has no products approved for commercial sale and generates revenue primarily through research partnerships rather than product sales, a common model in the biotechnology sub-industry. Its drug discovery approach relies heavily on computational and automated laboratory technologies rather than traditional manual screening methods.

Headlines to Watch Out For
  • Phase 1b/2 trial readouts for lead oncology candidates
  • Partnership milestone payments from Roche and Sanofi
  • Cash burn drives potential dilutive capital raise
Piotroski VR-10 (Strict) 0.0
Net Income: -559.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 6.40 > 1.0
NWC/Revenue: 874.8% < 20% (prev 740.1%; Δ 134.6% < -1%)
CFO/TA -0.24 > 3% & CFO -321.0m > Net Income -559.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.47 > 1.5 & < 3
Outstanding Shares: last quarter (529.3m) vs 12m ago 31.42% < -2%
Gross Margin: -34.44% > 18% (prev 6.43%; Δ -40.87% > 0.5%)
Asset Turnover: 5.01% > 50% (prev 4.58%; Δ 0.44% > 0%)
Interest Coverage Ratio: -336.6 > 6 (EBIT TTM -563.5m / Interest Expense TTM 1.67m)
Altman Z'' -1.94
A: 0.43 (Total Current Assets 709.6m - Total Current Liabilities 129.7m) / Total Assets 1.34b
B: -1.64 (Retained Earnings -2.19b / Total Assets 1.34b)
C: -0.43 (EBIT TTM -563.5m / Avg Total Assets 1.32b)
D: 3.26 (Book Value of Equity 1.02b / Total Liabilities 314.8m)
Altman-Z'' = -1.94 = D
Beneish M -3.64
DSRI: 0.27 (Receivables 13.6m/46.1m, Revenue 66.3m/59.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.89 (AQ_t 0.35 / AQ_t-1 0.40)
SGI: 1.11 (Revenue 66.3m / 59.7m)
TATA: -0.18 (NI -559.8m - CFO -321.0m) / TA 1.34b)
Beneish M = -3.64 (Cap -4..+1) = AAA
What is the price of RXRX shares?

As of July 08, 2026, the stock is trading at USD 3.84 with a total of 28,488,453 shares traded. Over the past week, the price has changed by +4.07%, over one month by +15.66%, over three months by +20.38% and over the past year by -22.11%.

Current recommended Stop Loss: 3.50 (which is 8.9% or 1.3 ATR below the current price).

Is RXRX a buy, sell or hold?

Recursion Pharmaceuticals has received a consensus analysts rating of 3.38. Therefore, it is recommended to hold RXRX.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RXRX price?
Analysts Target Price 6.6 72.9%
Recursion Pharmaceuticals (RXRX) - Fundamental Data Overview as of 07 July 2026
Market Cap USD = 2.02b (2.02b USD * 1.0 USD.USD)
P/S = 30.3713
P/B = 1.9759
Revenue TTM = 66.3m USD
EBIT TTM = -563.5m USD
EBITDA TTM = -479.5m USD
Long Term Debt = 7.18m USD (from longTermDebt, last quarter)
Short Term Debt = 22.4m USD (from shortTermDebt, last quarter)
Debt = 128.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 55.9m
Net Debt = -526.2m USD (calculated: Debt 128.3m - CCE 654.5m)
Enterprise Value = 1.49b USD (2.02b + Debt 128.3m - CCE 654.5m)
Interest Coverage Ratio = -336.6 (Ebit TTM -563.5m / Interest Expense TTM 1.67m)
EV/FCF = -4.57x (Enterprise Value 1.49b / FCF TTM -325.8m)
FCF Yield = -21.86% (FCF TTM -325.8m / Enterprise Value 1.49b)
 FCF Margin = -491.6% (FCF TTM -325.8m / Revenue TTM 66.3m)
 Net Margin = -844.5% (Net Income TTM -559.8m / Revenue TTM 66.3m)
 Gross Margin = -34.44% ((Revenue TTM 66.3m - Cost of Revenue TTM 89.1m) / Revenue TTM)
Gross Margin QoQ = -92.99% (prev 24.37%)
Tobins Q-Ratio = 1.11 (Enterprise Value 1.49b / Total Assets 1.34b)
Interest Expense / Debt = 1.30% (Interest Expense 1.67m / Debt 128.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -445.2m (EBIT -563.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.47 (Total Current Assets 709.6m / Total Current Liabilities 129.7m)
Debt / Equity = 0.13 (Debt 128.3m / totalStockholderEquity, last quarter 1.02b)
 Debt / EBITDA = 1.10 (negative EBITDA) (Net Debt -526.2m / EBITDA -479.5m)
 Debt / FCF = 1.61 (negative FCF - burning cash) (Net Debt -526.2m / FCF TTM -325.8m)
 Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -42.33% (Net Income -559.8m / Total Assets 1.34b)
RoE = -54.32% (Net Income TTM -559.8m / Total Stockholder Equity 1.03b)
RoCE = -54.31% (EBIT -563.5m / Capital Employed (Equity 1.03b + L.T.Debt 7.18m))
 RoIC = -36.23% (negative operating profit) (NOPAT -445.2m / Invested Capital 1.23b)
 WACC = 15.26% (E(2.02b)/V(2.15b) * Re(16.17%) + D(128.3m)/V(2.15b) * Rd(1.30%) * (1-Tc(0.21)))
Discount Rate = 16.17% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 43.96%
 [DCF] Fair Price = unknown (Cash Flow -325.8m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.64 | # QB: 0
Revenue Correlation: 64.43 | Revenue CAGR: 14.26% | SUE: -1.13 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.23 | Chg30d=+5.43% | Revisions=+40% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.23 | Chg30d=+2.13% | Revisions=+40% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.92 | Chg30d=+7.02% | Revisions=+67% | GrowthEPS=+36.3% | GrowthRev=-10.9%
EPS next Year (2027-12-31): EPS=-0.88 | Chg30d=-3.27% | Revisions=+30% | GrowthEPS=+4.2% | GrowthRev=+67.8%
[Analyst] Revisions Ratio: +65% (up=15, down=2)